Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Adaptive Biotechnologies Corporation    ADPT

ADAPTIVE BIOTECHNOLOGIES CORPORATION

(ADPT)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Adaptive Biotechnologies : Goldman Sachs Downgrades Adaptive Biotechnologies to Neutral From Buy, Adjusts Price Target to $63 From $74

03/03/2021 | 08:00am EDT


© MT Newswires 2021
All news about ADAPTIVE BIOTECHNOLOGIES CORPORATION
03/17ADAPTIVE BIOTECHNOLOGIES CORP  : Change in Directors or Principal Officers, Regu..
AQ
03/17Adaptive Biotechnologies Strengthens Expertise and Diversity of Board of Dire..
GL
03/08SECTOR UPDATE : Health Care Stocks Mixed Pre-Bell Monday
MT
03/08SECTOR UPDATE : Health Care
MT
03/08ADAPTIVE BIOTECHNOLOGIES  : Secures FDA Emergency Use Authorization For T-Cell-B..
MT
03/05ADAPTIVE BIOTECHNOLOGIES  : Gets FDA EUA for T-Detect to Confirm Recent or Prior..
DJ
03/05Adaptive Biotechnologies Announces FDA Emergency Use Authorization for T-Dete..
GL
03/05ADAPTIVE BIOTECHNOLOGIES CORP  : Change in Directors or Principal Officers (form..
AQ
03/03ADAPTIVE BIOTECHNOLOGIES  : Goldman Sachs Downgrades Adaptive Biotechnologies to..
MT
03/02ADAPTIVE BIOTECHNOLOGIES CORP  : Regulation FD Disclosure, Other Events (form 8-..
AQ
More news
Financials (USD)
Sales 2021 150 M - -
Net income 2021 -237 M - -
Net cash 2021 303 M - -
P/E ratio 2021 -23,3x
Yield 2021 -
Capitalization 5 627 M 5 627 M -
EV / Sales 2021 35,5x
EV / Sales 2022 24,6x
Nbr of Employees 622
Free-Float 92,6%
Chart ADAPTIVE BIOTECHNOLOGIES CORPORATION
Duration : Period :
Adaptive Biotechnologies Corporation Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ADAPTIVE BIOTECHNOLOGIES CORPORATION
Short TermMid-TermLong Term
TrendsBearishBearishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 8
Average target price 66,00 $
Last Close Price 40,42 $
Spread / Highest target 83,1%
Spread / Average Target 63,3%
Spread / Lowest Target 48,4%
EPS Revisions
Managers and Directors
NameTitle
Chad Robins Chairman & Chief Executive Officer
Julie Rubinstein President
Chad M. Cohen Chief Financial & Accounting Officer
Harlan Robins Chief Scientific Officer
Lance Baldo Chief Medical Officer
Sector and Competitors
1st jan.Capitalization (M$)
ADAPTIVE BIOTECHNOLOGIES CORPORATION-31.64%5 627
EXACT SCIENCES CORPORATION-3.01%21 228
GUARDANT HEALTH, INC.21.95%15 784
BGI GENOMICS CO., LTD.-5.19%8 067
INVITAE CORPORATION-9.11%7 473
IOVANCE BIOTHERAPEUTICS, INC.-34.94%4 437